Xanthorrhizol 产品活性：Xanthorrhizol 是从 Curcuma xanthorrhiza 中分离出来的，一种有效的抗菌剂。 产品来源： https://www.medchemexpress.cn/Xanthorrhizol.html 研究领域：Anti-infection 作用靶点：Bacterial 来源：植物 | 姜科 | 姜黄 | 植物 | 姜科 | Curcuma xanthorrhiza Roxb. 结构分类：萜类 | 倍半萜 | 酚类 | 单酚类 | 结构分类 In Vitro: Xanthorrhizol is a potential antibacterial agent from Curcuma xanthorrhiza against streptocpccus mutants. SEM analysis shows that, treatment of Candida species with MIC of Xanthorrhizol affects the external morphology of these yeasts. Cells incubated in the presence of Xanthorrhizol demonstrate a greater tendency to clump compared with the control cultures. Xanthorrhizol treated C. glabrata cells shows minor abnormalities without a smooth or a slightly awkward surface. Xanthorrhizol-treated Candida cells exhibit deformation and protrusions on the cell surface, which is more clearly demonstrated with C. guilliermondii and C. parapsilosis. In general, Candida exposed to, Xanthorrhizol at concentrations 1 x MICs exhibits substantial ultrastructural abnormalities such as shape deformation, protrusion, rugged cells surface, and clumping. In Vivo: Ear edema induced by the topical application of TPA is suppressed by pre-treatment with Xanthorrhizol in a doserelated manner (P<0.005). Topical application of Xanthorrhizol alone does not induce ear edema in mice. All the mice treated with 7.5 nM TPA for 19 weeks after initiation by DMBA developed an average of 15.5±2.3 skin tumors per mouse (tumor multiplicity). Pre-treatment with 2 and 6 μM Xanthorrhizol reduces tumor multiplicity to 6.9±1.1 (P<0.005) and 4.0±1.1 (P<0.005), respectively, at 19 weeks. In addition, Xanthorrhizol at 2 and 6 μM dose dependently lowers the percentage of tumor-bearing mice (tumor incidence) to 80 and 57%, respectively, at the termination of the experiments. Furthermore, the tumor multiplicity (P<0.05) and incidence are reduced in the DMBA-initiated mice that are topically treated with Xanthorrhizol for 6 weeks after the induction of papillomas with hyperplasia, mild dysplasia and moderate dysplasia by topical TPA application for 6, 18 and 24 weeks, respectively. The increased ODC expression in mouse epidermis with acute inflammation and tumor promotion induced by TPA is inhibited by pre-treatment with Xanthorrhizol in a dose-dependent manner. The topical application of Xanthorrhizol after the induction of papillomas with hyperplasia and dysplasia also potently inhibited ODC expression. 相关产品：Rapamycin | Doxorubicin hydrochloride | Bafilomycin A1 | Dimethyl sulfoxide | Dexamethasone | Puromycin dihydrochloride | Staurosporine | Actinomycin D | Etoposide | G-418 disulfate | Nigericin sodium salt | 5-Azacytidine | Brefeldin A | CCCP | Estradiol | Ionomycin | Hygromycin B | Mitomycin C | Resveratrol | Tunicamycin | Everolimus | Doxycycline hyclate | Tacrolimus | Methotrexate | Streptozotocin | Lactate sodium | Neomycin sulfate | Acetaminophen | Anisomycin 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。